How to get TRT, starting with the step the funnel is built to skip

What actually gets you a TRT prescription

Two things, and they are not negotiable in either direction. A low testosterone level on its own is not a diagnosis, and symptoms on their own are not a diagnosis. The AUA states it as guideline statement 3: The clinical diagnosis of testosterone deficiency is only made when patients have low total testosterone levels combined with symptoms and/or signs. The panel spells out the consequence in its own definitions section: Thus, a patient is considered testosterone deficient and a candidate for testosterone therapy only when he meets both criteria.

That is why the questionnaire at the top of a telehealth funnel cannot get you there. It collects half of the requirement. The other half is a laboratory result, twice, and it is the half that can come back and say no.

4 labels, 4 times, same sentence

These are the 4 testosterone prescribing informations read for this page, covering an injectable generic, a subcutaneous auto-injector and two oral capsules. Every one of them puts the two-draw confirmation ahead of the first dose, and not one of them prints a number.

Read the Limitation of Use line on all 4 of them together. Every label says that safety and efficacy in men with age-related hypogonadism have not been established, and 2 of them add that this is also called late-onset hypogonadism. The approved indications are primary hypogonadism and hypogonadotropic hypogonadism, which are conditions with a cause behind them. The AUA opens its own statement of purpose on the same point: Testosterone testing and prescriptions have nearly tripled in recent years; however, it is clear from clinical practice that there are many men using testosterone without a clear indication. Worth knowing before an intake form tells you your symptoms are a diagnosis.

What testosterone level qualifies you, and why the number moves

The AUA prints a figure. Guideline statement 1: Clinicians should use a total testosterone level below 300 ng/dL as a reasonable cut-off in support of the diagnosis of low testosterone. That is a Moderate Recommendation; Evidence Level: Grade B, which is the guideline's own way of saying the panel is confident about the direction and less confident about the exact line.

Its discussion says why. A number of medical societies (e.g., American Society of Andrology, Endocrine Society, European Association of Urology, European Academy of Andrology, International Society of Andrology, International Society for the Study of the Aging Male) have used various thresholds to define low total testosterone, ranging from 230-350 ng/dL. A man whose morning total testosterone comes back at 310 sits above the AUA line and inside the range other societies have used. The threshold is a judgement call, so a clinic that will not tell you which one it applies has told you something.

The two guidelines also differ on how the blood is drawn. The AUA asks for two early morning measurements. The Endocrine Society adds fasting. Its first recommendation reads: We recommend measuring fasting morning total T concentrations using an accurate and reliable assay as the initial diagnostic test. Its second: We recommend confirming the diagnosis by repeating the measurement of morning fasting total T concentrations. Eat breakfast before the draw and you have satisfied one guideline while missing the other, which is the kind of detail an order form will never mention.

Two more practical points from the AUA discussion, both of which change what you should ask for. On where the blood goes: The Panel recommends that clinicians use the same laboratory with the same method/instrumentation for serial total testosterone measurement. On timing: At this time, there is no definitive evidence indicating what the optimal time interval should be between the two separate tests. And on what happens when the two results disagree, which is common: If a patient's first test is <300 ng/dL and the second test is normal, then the clinician should use his or her judgment to determine if a third test is to be used as a control.

The steps, in the order a competent process runs them

Five stages. The order is the point. A funnel that reaches stage four without finishing stage two has removed a stage, and the stage it removed is the one that can end with a no.

1. Stage 1

   Symptoms and signs, which are the half that does not prove anything on its own

   The AUA is blunt about why this stage cannot carry the diagnosis on its own: The challenge for clinicians is that the symptoms that have been associated with low testosterone levels are very non-specific and can be manifestations of other conditions (e.g., chronic fatigue, chronic stress, a depressed state). Statement 3 therefore requires the symptoms be combined with a low level. Statement 5 goes further on the intake form itself: The use of validated questionnaires is not currently recommended to either define which patients are candidates for testosterone therapy or to monitor symptom response in patients on testosterone therapy. That one is a Conditional Recommendation; Evidence Level: Grade C, the panel's weakest tier of advice. It still points the opposite way from a symptom quiz at the top of a funnel.

2. Stage 2 · the gate

   Two total testosterone measurements, two separate mornings

   AUA statement 2: The diagnosis of low testosterone should be made only after two total testosterone measurements are taken on separate occasions with both conducted in an early morning fashion.That carries the guideline's highest confidence rating, Strong Recommendation; Evidence Level: Grade A. It is also the requirement the labels put ahead of the first dose. Two appointments, two mornings, and the second one can end the process. Nobody draws blood over a video call, so this is the stage where a fully online path becomes physical.

3. Stage 3

   The rest of the workup, still before the first dose

   Confirming the level is not the same as finding out why it is low. The Endocrine Society is explicit: In men determined to have androgen deficiency, we recommend additional diagnostic evaluation to ascertain the cause of androgen deficiency. The AUA lists what that means in practice, and each item below carries its own numbered guideline statement and its own confidence grade.

   • Statement 6. In patients with low testosterone, clinicians should measure serum luteinizing hormone levels. (Strong Recommendation; Evidence Level: Grade A) Statement 7 adds prolactin where LH is low or low-normal. This is the pair that tells the two approved indications apart, and the JATENZO label says so itself, in full: Primary hypogonadism (congenital or acquired): testicular failure due to conditions such as cryptorchidism, bilateral torsion, orchitis, vanishing testis syndrome, orchiectomy, Klinefelter syndrome, chemotherapy, or toxic damage from alcohol or heavy metals. These men usually have low serum testosterone concentrations and gonadotropins (follicle-stimulating hormone [FSH], luteinizing hormone [LH]) above the normal range. against Hypogonadotropic hypogonadism (congenital or acquired): gonadotropin or luteinizing hormone-releasing hormone (LHRH) deficiency or pituitary-hypothalamic injury from tumors, trauma, or radiation. These men have low testosterone serum concentrations but have gonadotropins in the normal or low range. A testosterone number on its own cannot say which of those you have.
   • Statement 10. Men with testosterone deficiency who are interested in fertility should have a reproductive health evaluation performed prior to treatment. (Moderate Recommendation; Evidence Level: Grade B) The fork this opens has its own section below.
   • Statement 11. Prior to offering testosterone therapy, clinicians should measure hemoglobin and hematocrit and inform patients regarding the increased risk of polycythemia. (Strong Recommendation; Evidence Level: Grade A) Without this baseline, the every-3-months check the labels ask for later has nothing to be compared against.
   • Statement 12. PSA should be measured in men over 40 years of age prior to commencement of testosterone therapy to exclude a prostate cancer diagnosis. (Clinical Principle)

4. Stage 4

   The prescription, and the fact that it is a controlled substance

   Testosterone Cypionate Injection contains testosterone, a Schedule III controlled substance in the Controlled Substances Act. That changes the mechanics of a subscription in a way nobody advertises. 21 CFR 1306.22(a) reads: No prescription for a controlled substance listed in Schedule III or IV shall be filled or refilled more than six months after the date on which such prescription was issued. No prescription for a controlled substance listed in Schedule III or IV authorized to be refilled may be refilled more than five times. So a twelve-month course of testosterone takes at least two prescriptions, which puts at least one point in the year where a clinician has to write a new one for the shipments to continue. What that renewal consists of is the question worth asking before you subscribe.

5. Stage 5

   Monitoring, including the conversation about stopping

   3 of the 4 labels ask for hematocrit approximately every 3 months to detect increased red cell mass and polycythemia. The older generic label asks for it periodically during long-term administration and names no interval. That looser wording sits on the vial 2 of the 5 clinics on our roster list by name. The AUA adds an initial follow-up level after an appropriate interval to confirm the target was reached, then levels every 6 to 12 months. The Endocrine Society adds prostate cancer risk evaluation during the first year.

   Statement 31 is the one no subscription business has an incentive to raise: Clinicians should discuss the cessation of testosterone therapy three to six months after commencement of treatment in patients who experience normalization of total testosterone levels but fail to achieve symptom or sign improvement. If your level normalized and you still feel the same at three months, that conversation is owed to you, and the guideline is where you can point to say so.

What telehealth can and cannot legally do with testosterone

Testosterone is a Schedule III controlled substance, so the default federal rule is the strict one. Under the Ryan Haight Online Pharmacy Consumer Protection Act of 2008, a practitioner may remotely prescribe a controlled substance only after conducting at least one in-person medical evaluation of that patient in the course of their practitioner-patient relationship, subject to a set of statutory exceptions. Everything about buying testosterone from a website you have never physically visited runs through one of those exceptions.

The exception currently in force is a temporary rule with a date on it. The DEA, jointly with HHS, published the Fourth Temporary Extension of COVID-19 Telemedicine Flexibilities for Prescription of Controlled Medications at 90 FR 61301 on December 31, 2025. Its DATES line reads: This rule is effective January 1, 2026 through December 31, 2026.

Four conditions, and the second one is about how you and the clinician actually communicate

The authorization is conditional. 21 CFR 1307.41 lists what a prescription issued under it has to satisfy:

1. The prescription is issued for a legitimate medical purpose by a practitioner acting in the usual course of professional practice;
2. The prescription is issued pursuant to a communication between a practitioner and a patient using an interactive telecommunications system referred to in 42 CFR 410.78(a)(3);
3. The practitioner is authorized under their registration under 21 CFR 1301.13(e)(1)(iv) to prescribe the basic class of controlled substance specified on the prescription, or exempt from obtaining a registration to dispense controlled substances under 21 U.S.C. 822(d); and
4. The prescription is consistent with all other requirements of 21 CFR part 1306.

The second condition is the one to read twice. It requires a communication between a practitioner and a patient through an interactive telecommunications system. In its own description of the flexibilities, the rule says they authorized practitioners to prescribe Schedule II-V controlled medications via audio-video telemedicine encounters, with a narrow audio-only carve-out for opioid use disorder medication that has nothing to do with testosterone. Whether an intake questionnaire on its own satisfies that condition is a question for a clinic's compliance counsel, and this page cannot settle it. What the rule plainly asks for is a communication between two people. The first condition is easier to overlook and carries just as much: the prescription has to be issued for a legitimate medical purpose by a practitioner acting in the usual course of professional practice. Skipping the confirmatory draws puts weight on that clause, and the weight lands on the clinic.

Federal law is also the floor rather than the ceiling. The statutory exceptions the DEA is operating under require that the practice be in accordance with applicable Federal and State laws, so a state medical board or a state controlled-substance statute can require more than the federal rule does, including an in-person evaluation the DEA is currently waiving. Where you live changes the answer, and the clinic is the one that has to know.

The routes, and what the first month actually buys

Here is the finding that surprised us. Of the 5 platforms in our men's wing, 3 publish a real recurring monthly all-in price, and those 3 land between $99 and $139. The whole spread is $40. The advertised monthly prices have converged. What still differs between these clinics is what they require before the first dose, and that shows up in the first month.

4 of the 5 publish a first-month total, and for 4 of them it is higher than the monthly price they advertise. 4 of those 4 strings price a diagnostic line, worded as labs, a baseline test or an assessment depending on the clinic. 1 of them names a second draw. Read that against the labels above. The requirement that comes first in the dosing instructions is the one the published pricing does not account for, which means either the second draw is included and nobody says so, or it is not included and nobody says that either. Ask before you pay, and ask what happens to the money if the second result comes back normal.

Two more things the roster settles. None of the 5 bills insurance, so every figure above is cash. And MangoRx lists an oral testosterone built on Kyzatrex, one of the 4 labels quoted above. Our roster records that as reported rather than verified, and it is a separate line from the headline injectable programme, so read it as the label standing behind one product on the menu.

For the per-clinic arithmetic, including what each one charges for labs and follow-ups, read what TRT actually costs. For the price-sorted version, cheapest online TRT. For the route that runs through a doctor and a plan instead, does insurance cover TRT. For the scores and transparency grades behind the names above, the men's rankings.

If you want children, this is the fork, and it comes before the prescription

Testosterone supplied from outside suppresses the signal driving your own production, and sperm production goes with it. The AUA writes this as one of the few flat prohibitions in the whole document. Statement 23: Exogenous testosterone therapy should not be prescribed to men who are currently trying to conceive. That is a Strong Recommendation; Evidence Level: Grade A, the guideline's highest confidence level. Statement 16 adds that the long-term impact on spermatogenesis has to be discussed with anyone interested in future fertility, also Strong at Grade A, and statement 10 asks for a reproductive health evaluation before treatment. The Endocrine Society opens its own list of reasons to hold off with the same one: We recommend against starting T therapy in patients who are planning fertility in the near term, before the sentence continues into a set of unrelated contraindications.

The AUA names the alternatives in statement 27: Clinicians may use aromatase inhibitors, human chorionic gonadotropin, selective estrogen receptor modulators, or a combination thereof in men with testosterone deficiency desiring to maintain fertility. That carries a Conditional Recommendation; Evidence Level: Grade C, a real step down in confidence from the Grade A prohibition above it, and it should be read that way. Enclomiphene is the selective estrogen receptor modulator from that list that telehealth actually sells. Hone Health, MangoRx and Maximus list it, 3 of the 5 clinics on our roster.

No FDA-approved enclomiphene product exists. Checked on August 16, 2026 by openFDA drug label search on substance name and generic name, both returning no matches. Everything on this page about what a testosterone label requires therefore does not apply to enclomiphene, because there is no enclomiphene label. The full comparison, including what the trials showed and what compounding means for it, is on our enclomiphene page.

Related

• Online TRT clinics, scored and graded the 5 platforms, ranked by editorial score
• What TRT actually costs membership, medication and labs added up per clinic
• Cheapest online TRT sorted by true monthly cost
• Does insurance cover TRT the route through a plan instead of a card
• Enclomiphene against TRT the fertility-preserving fork
• Testosterone side effects what the labels report